Interpace Biosciences (IDXG) Proxy filing summary

Executive summary

• Annual Meeting scheduled for August 20, 2026, will be held virtually to increase access and participation.

• Stockholders of record as of June 29, 2026, are eligible to vote on key proposals, including amendments to the Certificate of Incorporation, a reverse stock split, new equity and employee stock purchase plans, director elections, executive compensation, and auditor ratification.

• Board recommends voting in favor of all proposals, emphasizing alignment with company growth, governance modernization, and talent retention.

Voting matters and shareholder proposals

• Proposals include amending and restating the Certificate of Incorporation, authorizing a reverse stock split (1-for-2 to 1-for-10), approving the 2026 Equity Incentive Plan, and the 2026 Employee Stock Purchase Plan.

• Director elections depend on the outcome of the charter amendment: five unclassified directors if approved, or staggered terms if not.

• Advisory vote on executive compensation and ratification of EisnerAmper as independent auditor are included.

• Board unanimously recommends a vote FOR all proposals.

Board of directors and corporate governance

• Board currently consists of five members, with a mix of industry, financial, and operational expertise.

• Proposed charter amendments would declassify the board, eliminate supermajority voting, and enhance director/officer indemnification.

• Committees include Audit, Compensation, Nominating, and Regulatory Compliance, all composed of independent directors except the CEO.

• Board leadership combines CEO and Chairman roles for unified direction.